Why is Mesoblast (ASX: MSB) on investors’ radar
Highlights COVID-19 ARDS stemming from COVID-19 infection is a leading cause of death among COVID-19 patients. Mesoblast Limited (ASX: MSB) is developing and testing remestemcel-L for reducing the mortality occurring due to COVID-19 ARDS in adults. As a next step, the company is expected to resubmit the current Biologic License Application (BLA) with a six-month review period. Rising coronavirus cases are increasing, posing a grave threat, especially in Queensland and Western Australia, as the number of cases topped 800 in the past few days. However, with the surge in COVID-19 cases, diseases or symptoms arising from the infection also take a toll on humans. For example, In COVID-19 ARDS (Acute Respiratory Distress Syndrome), the organs are deprived of oxygen as the air-sacs of the lungs are filled with fluids. ARDS has been identified as the leading reason for death for ventilator-dependent COVID-19 patients. Mesoblast Limited ( ASX: MSB ) is an Australian biopharmaceutical comp...